<DOC>
	<DOCNO>NCT02172105</DOCNO>
	<brief_summary>Study evaluate safety , tolerability , pharmacokinetics BI 1744 CL healthy Japanese male volunteer .</brief_summary>
	<brief_title>Multiple Rising Inhalative Doses BI 1744 CL Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy Japanese men : According result complete medical history , physical examination , vital sign ( blood pressure pulse rate ) , 12lead ECG , clinical laboratory test Age ≥20 ≤35 year Body mass index ( BMI ) ≥18.5 ≤25.0 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Subjects must able inhale medication competent manner Respimat®inhaler Any find medical examination ( include , blood pressure pulse rate ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug drug administration trial Use prescription nonprescription drug within 10 day drug administration trial . However , overthecounter drug external application ( lubricant eye drop contact lens , insect bite reliever ) shall allow Participation another trial investigational drug within four month drug administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day : corresponds ca . 3 large bottle beer , 3 gous ( ca . 540 cc ) Japanese sake , 6 shot whisky , 6 glass wine 6 glass Japanese shochu , distil alcoholic beverage ) Drug abuse Blood donation ( 100 mL within four week drug administration trial ) Excessive physical activity ( within one week administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) long QT syndroms A history additional risk factor torsades de pointes ( TdP ) ( e.g. , heart failure , hypokalemia ) cardiac arrhythmias hyperthyroidism Disagree adequate contraception ( subject use condom partner use oral contraception intrauterine device [ IUD ] ) study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>